CAMBRIDGE, Mass -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced preliminary data from the first part of a Phase 2 clinical study conducted by the Company of IMO-2055 monotherapy in ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced favorable safety and efficacy results from a Phase 1b study of IMO-2055, a TLR9 agonist, in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback